Leadless Electrocardiogram (ECG) Evaluation Study
Launched by MEDTRONIC CARDIAC RHYTHM AND HEART FAILURE · Feb 15, 2011
Trial Information
Current as of June 27, 2025
Completed
Keywords
ClinConnect Summary
The leadless electrocardiogram (LECG) is a new technology incorporated into the Consulta CRT-P to obtain an ECG signal from the Consulta CRT-P similar to a surface ECG obtained from the device programmer (PECG) or an external ECG machine. The LECG signals are measured from three electrodes mounted on the outside of the pacemaker housing and provides an electrical far field signal of the electrical activity of the heart. The LECG provides three ECG channels as different projections of the electrical activity of the heart, similar to the surface ECG. Clinical interest of LECG is threefold. Fi...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • patient with a CRT-P indication and
- • patient who has signed an informed consent form.
- Exclusion Criteria:
- • patient younger than 18 years and/or
- • unable to complete the 1-Month Follow-up visit and/or
- • legally incompetent or illiterate and therefore unable to provide an informed consent
About Medtronic Cardiac Rhythm And Heart Failure
Medtronic Cardiac Rhythm and Heart Failure is a leading division of Medtronic, dedicated to advancing innovative therapies for patients with cardiac rhythm disorders and heart failure. With a commitment to improving patient outcomes, this division focuses on developing cutting-edge medical devices and solutions that enhance the management of arrhythmias and heart failure. Leveraging extensive research and clinical expertise, Medtronic Cardiac Rhythm and Heart Failure aims to transform patient care through evidence-based approaches and a robust pipeline of groundbreaking technologies. Their work not only addresses immediate clinical challenges but also contributes to the long-term health and well-being of individuals with complex cardiac conditions.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Paris, , France
Patients applied
Trial Officials
Françoise HIDDEN-LUCET, MD
Principal Investigator
Hôpital La Pitié Salpêtrière, Paris, France
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials